ReActiv8® LIFE

RESTORE CONTROL
RESTORE FUNCTION
RESTORE STABILITY



TREAT THE CAUSE...




Restorative treatments focus on improving function for patients by addressing the underlying cause.

...<u>NOT</u> THE SYMPTOMS

Palliative treatments focus on blocking pain through Spinal Cord Stimulation, oral medication, injections, or burning nerves.



ReActiv8 aims to restore neuromuscular control of the lumbar spine to increase function and stability, leading to a reduction of pain.



Mechanical Chronic Low Back Pain



Mechanical chronic low back pain results from an injury or stress on the tissues surrounding the spine, including soft tissues, muscles, bones, and joints.

Often times, this type of pain is due to impaired muscle control and neural inhibition of the **multifidus**, which is the largest stabilizing muscle in your back. When this neuromuscular inhibition occurs, there can be misalignment of the spine, causing uncontrolled loading and pain.

ReActiv8 overcomes neural inhibition and allows the body to regain control of the multifidus, allowing it to provide functional lumbar stability and reduce mechanically based pain.

ReActiv8®



CONTROL

of neural signals activating your multifidus muscle

FUNCTION

of the multifidus muscle to provide stability to the spine

STABILITY

of the spine to reduce pain



- A generator is connected to two electrical leads, which are positioned to stimulate the nerves that control your multifidus muscle.
- You control your twice-daily, 30-minute therapy sessions, which can feel like a deep tissue massage.



Long-Term Clinical Outcomes

Pain and Function Improvements




8 out of 10 patients reported substantial improvements in pain and/or function






7 out of 10 patients voluntarily eliminated or reduced their opioid intake*

*Percent of patients that were on opioids at baseline: (1-year=31/65), (2-Year=34/57), (3-Year=36/51).





Patients experience **progressive long-term improvements** in pain and function, over time, demonstrating a durable, consistent, and restorative result.



What makes ReActiv8 unique?

ReActiv8 is designed to address the underlying cause of mechanical low back pain by helping patients restore neuromuscular control of the multifidus muscle.

Why is the multifidus muscle important?

The multifidus muscle is the key stabilizing muscle in the lower back. A single injury to the back can cause impaired muscle control of the multifidus. This lack of muscle control can decrease the spine's functional stability, leaving the spine susceptible to further injury and overloading. Restoring the neuromuscular control of the multifidus muscle can stabilize the spine, thereby increasing function and decreasing pain.

Is ReActiv8 right for me?

Talk to you doctor to see if you are a candidate.

Scan the QR code to start your ReActiv8 iourney today!





Gilligan C., Volschenk W., Russo M., Green M., Gilmore C., Mehta V., Deckers K., De Smedt K., Latif U., Sayed D., Georgius P., Gentile J., Mitchell B., Langborst M., Huygen F., Baranidharan G., Patel V., Mironer E., Ross E., Carayannopoulos A., Hayek S., Gulve A., Van Buyten J.-P., Tohmeh A., Fischgrund J., Lad S., Ahadian F., Deer T., Klemme W., Rauck R., Rathmell J., Schwab F., Maislin G., Heemels J.P., Eldabe S., 2022. Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction. Neuromodulation 202;: :1-11.

The ReActiv8 System is indicated as an aid in the management of intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing. For important safety and product information, visit www.mainstaymedical.com/safety

The ReActiv8-B Trial demonstrated a strong safety profile for ReActiv8 (particularly compared to spinal cord stimulators). Among the 204 randomized patients, 8 serious adverse events (SAEs) related to the device/procedure were reported (4 percent overall) at the 120-day mark. There were no unanticipated device/process SAEs and no instances of lead migration. (Among all adverse events, 53 percent occurred within the first 30 days, and 83 percent were resolved.)